Skip to content
Stock screener

ALNY Alnylam Pharmaceuticals, Inc. stock chart & analysis

Conviction 47HealthcareScan · Fri, Nov 6, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) closed at $155.94 (-0.46%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 22, RS Rating 8, -67.5% from its 52-week high, -60.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.

ALNY$155.94-0.46%
ResistanceSupportVol 14Insider sellCongress buyCongress sell
Loading chart…
Alnylam Pharmaceuticals, Inc.Pharmaceutical Preparationswww.alnylam.com ↗
Price155.94
Change-0.46%
Gap-0.57%
Rel volume1.30×
Avg volume2.8M
Avg $ vol517.98M
SMA 20204.95
SMA 50228.57
SMA 200280.39
Price vs 50-31.77%
Price vs 200-44.38%
MA stackbearish
50/200 cross—
Supertrenddown · 191.64
RSI (14)22
MACD hist-6.28
MACD crossbear · 6d
Stoch %K / %D2 / 3
ADX (14)27
+DI / −DI14 / 39
RSI divergence—
MACD divergence—
ATR %7.25%
ADR %4.75%
52w high479.79
52w low154.59
From 52w high-67.50%
Above 52w low+0.88%
New 52w highNo
SqueezeOff
Bollinger width62.82%
%B0.12
Donchian pos1.61%
Donchian high238.96
Donchian low154.59
AVWAP (52w high)285.20
vs AVWAP high-45.32%
AVWAP (52w low)156.57
vs AVWAP low-0.40%
OBV trendDown
Chaikin MF (20)-0.48
Today vs 20d1.30×
Avg vol (14d)3.48M
Avg vol (20d)2.8M
Avg $ vol (20d)517.98M
Market cap20.89B
RS Rating8 / 99
RS 3m (vs SPY)-23.26%
RS 6m (vs SPY)-46.85%
RS line new highNo
Trend template0/8
Technical rank11.7
1 week-5.49%
1 month-30.55%
3 months-28.13%
6 months-47.15%
1 year-64.11%
YTD-60.78%
P/E66.57
P/B5.80
P/S5.62
P/FCF44.88
EPS2.33
Div yield—
ROE8.71%
ROA3.92%
Debt/Eq0.19
Current2.48
EV/EBITDA35.55
Gross margin81.77%
Net margin8.45%
Rev growth65.19%
EPS growth212.79%
Price target313.47
Target upside101.01%
Analyst ratingBuy
Institutional110.65%
Ent. value19.81B
Revenue1.46B
Net income2.17B
Gross profit1.1B
Free cash flow465.38M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out133.51M
Employees2.5K
ListedFri, May 28, 2004
Free float132.42M
Float %99.9%
Short interest—
Days to cover—
Short volume31.2%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est$15.72 vs $1.46
Last surprise+976.7% beat
Setup gradeD
Conviction47 / 100
Pattern quality—
Tech rank11.7 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance256.39
Support185.73
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

ALNY technical analysis

Trend

ALNY is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 31.8% below the 50-day ($228.57) and 44.4% below the 200-day ($280.39). ADX(14) at 27 points to a strong, established trend. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 22, in oversold territory. MACD crossed below its signal line 6 sessions ago. Its RS Rating of 8 puts its weighted 12-month performance ahead of about 8% of the US market.

Volume and volatility

Volume on the latest session ran 1.3× its 20-day average. It trades about $518.0M a day on average. ATR(14) is $11.31, 7.2% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.48) shows distribution.

Key levels

The chart pattern's support is $185.73 and its resistance $256.39. The 52-week range is $154.59 to $479.79; price is 67.5% below the high and 0.9% above the low. The VWAP anchored at the 52-week high is $285.20, above price.

Performance

ALNY returned -5.5% (1 week), -30.6% (1 month), -28.1% (3 months), -47.1% (6 months), -64.1% (1 year), -60.8% (year to date).

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Pharmaceutical Preparations · Listed 2004 · 2,500 employees

Recent news

Congress activity

Disclosed STOCK Act trades in ALNY · 2 recent

All disclosures →
MemberSideAmount
Cory A Booker
Cory A Booker
senate · D · NJ · traded 2026-08-11
Sell$1K–$15K
Jefferson Shreve
Jefferson Shreve
house · R · IN · traded 2025-05-12
Sell$15K–$50K

Insider activity

SEC Form 4 transactions in ALNY · open-market 6 sells

InsiderSideShares
SUPRAN BRYAN
EVP, CLO and Secretary · Common Stock · 2026-10-02
Sell1.76K
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Sell495
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Other—
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Sell17
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Sell1.18K
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Exercise3.83K
PYOTT DAVID E I
Director · Stock Option (Right to Buy) · 2026-06-01
Exercise3.83K
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Sell1.22K
Cravatt Benjamin
Director · Stock Option (Right to Buy) · 2026-06-01
Grant4.39K
PYOTT DAVID E I
Director · Common Stock · 2026-06-01
Sell921

SEC filings

EDGAR filings in ALNY · 9 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.